Somayeh Ghafari

Somayeh Ghafari

Auto-generated profile, based on publicly available information

Somayeh Ghafari

Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
PDF file
FFFanak Fahimi
Fanak Fahimi
SGSomayeh Ghafari
Somayeh Ghafari
HJHamidreza Jamaati
Hamidreza Jamaati
SBShadi Baniasadi
Shadi Baniasadi
PTPayam Tabarsi
Payam Tabarsi
SHSeyed Mohammad Reza Hashemian
Seyed Mohammad Reza Hashemian
Background and Aims: Ventilator-associated pneumonia (VAP) is one of the most common Intensive Care Unit (ICU)-acquired infection. The aim of this study was to compare the clinical outcome of continuous and intermittent administration of piperacillin-tazobactam by serial measurements of the Clinical Pulmonary Infection Score (CPIS). Subjects and Methods: Groups were designed as parallel and the study was designed as quasi-experimental and conducted at a semi-closed ICU between September 2008 and May 2010. Patients received 3.375 g (piperacillin 3 g/tazobactam 0.375 g) either through intermittent infusion every 6 h for 30 min [Intermittent Infusion (II) group; n = 30] or through continuous infusion every 8 h for 4 h [Continuous Infusion (CI) group; n = 31]. CPIS was used to assess the clinical diagnosis and outcome of VAP patients. Results: Sex, age, Acute Physiology and Chronic Health Evaluation II II score on ICU admission, diagnosis and underlying disease of VAP patients were not significantly different in the CI (n = 31) and II (n = 30) groups. Duration of mechanical ventilation, length of stay, total number of antibiotics used per patient and duration of piperacillin/tazobactam treatment were similar in both groups. Mortality rates of VAP patients were similar between both groups during hospitalization. Conclusion: There was no significant difference in clinical outcomes of patients receiving piperacillin-tazobactam via CI or II when measured by serial CPIS score.

30 January 2020 in Journal of Pharmacy Practice and Research
Verified
Journal Article
Closed access
PDF file
ELElahe Laali
Elahe Laali
AGAzim Ghorbani
Azim Ghorbani
SNSheyda Najafi
Sheyda Najafi
ASAmir Sarayani
Amir Sarayani
SGSomayeh Ghafari
Somayeh Ghafari
ZJZahra Jahangard‐Rafsanjani
Zahra Jahangard‐Rafsanjani

9 January 2024 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RSReza Sinaei
Reza Sinaei
MNMohammad Javad Najafzadeh
Mohammad Javad Najafzadeh
SGSomayeh Ghafari
Somayeh Ghafari
AHAli Hosseininasab
Ali Hosseininasab
APAbbas Pardakhty
Abbas Pardakhty
FGFatemeh Goharriz
Fatemeh Goharriz
Background: Several coronavirus disease 2019 (COVID-19) vaccines, utilizing different platforms, have successfully obtained emergency clinical use authorization to prevent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections. Most published data from COVID-19 vaccine trials have frequently observed mild-to-moderate side effects, with varying severity depending on various vaccine types. Objectives: This study aimed to estimate the prevalence of side effects associated with four types of COVID-19 vaccines among vaccinated healthcare workers following the first and second vaccine doses and to identify possible risk factors for COVID-19 vaccine side effects. Methods: This cross-sectional study was conducted from April 2021 to March 2022 by administering a questionnaire and conducting direct interviews with healthcare workers in Kerman, southeastern Iran, who had received 2 or more doses of COVID-19 vaccines. Results: Out of 861 individuals enrolled in the study, 38.7% received Sputnik, 32.4% AstraZeneca, 19.6% Covaxin, and 9.3% Sinopharm vaccines. Overall, the most common side effects after the first and second doses included general symptoms, fever and chills, injection site reactions, neurological symptoms, and gastrointestinal symptoms. Furthermore, the frequency of symptoms significantly reduced after the second dose. Conclusions: General symptoms and injection site reactions were significantly more common after receiving the first dose of vaccines compared to the second dose. No severe vaccine side effects were observed in this study. However, further research is required to evaluate the long-term symptoms and safety profiles of COVID-19 vaccines.